BioCardia Announces $4.4 Million Financing
BioCardia, a US-based cellular therapy company focused on cardiovascular and pulmonary diseases, raised $4.4 million through a share sale to extend its cash runway into early 2027. The financing supports the anticipated submission of its CardiAMP cell therapy to Japan's PMDA regulatory authority in Q4 2026 and potential commercial launch. The compa…